The immunology space has evolved from reliance on broadly immunosuppressive treatment to the approval of multiple targeted disease modifying agents. Current immunology dynamics the REACH team is tracking include:
- “Pipeline in a product” emerging therapies like efgartigimod
- Novel mechanisms of action in development that offer more targeted approaches (e.g., IgG regulation, complement inhibition, T- and B-cell targets)
- Increasing competition in markets like Hereditary Angioedema (HAE)
Search Immunology diseases we cover